Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$7.24
-0.38-4.99%
At close: -
$7.25
0.010000.14%
After Hours: Jun 18, 7:09 PM EDT
Comments
Loading...
Cogent Biosciences Analyst Ratings and Price Targets | NASDAQ:COGT | Benzinga
Cogent Biosciences Inc has a consensus price target of $16.9 based on the ratings of 11 analysts. The high is $26 issued by Guggenheim on June 13, 2023. The low is $7 issued by Baird on May 7, 2025. The 3 most-recent analyst ratings were released by JP Morgan, HC Wainwright & Co., and Baird on May 29, 2025, May 20, 2025, and May 7, 2025, respectively. With an average price target of $14.67 between JP Morgan, HC Wainwright & Co., and Baird, there's an implied 102.30% upside for Cogent Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
HC Wainwright & Co.
Baird
Scotiabank
Citigroup
1calculated from analyst ratings
Analyst Ratings for Cogent Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/17/2025 | Buy Now | — | Needham | Ami Fadia60% | — | Reiterates | Hold → Hold | Get Alert |
| 05/29/2025 | Buy Now | 244.83% | JP Morgan | Anupam Rama60% | $21 → $25 | Maintains | Overweight | Get Alert |
| 05/20/2025 | Buy Now | 65.52% | HC Wainwright & Co. | Robert Burns46% | $14 → $12 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | -3.45% | Baird | Joel Beatty69% | $8 → $7 | Maintains | Neutral | Get Alert |
| 03/07/2025 | Buy Now | 134.48% | Scotiabank | Louise Chen58% | → $17 | Initiates | → Sector Outperform | Get Alert |
| 02/27/2025 | Buy Now | 10.34% | Baird | Joel Beatty69% | $10 → $8 | Maintains | Neutral | Get Alert |
| 02/26/2025 | Buy Now | — | Needham | Ami Fadia60% | — | Reiterates | Hold → Hold | Get Alert |
| 01/14/2025 | Buy Now | 93.1% | HC Wainwright & Co. | Robert Burns46% | $17 → $14 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | 106.9% | Needham | Ami Fadia60% | $15 → $15 | Downgrade | Buy → Hold | Get Alert |
| 12/11/2024 | Buy Now | — | HC Wainwright & Co. | Robert Burns46% | — | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | 106.9% | Needham | Ami Fadia60% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 12/09/2024 | Buy Now | 106.9% | Needham | Ami Fadia60% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 189.66% | JP Morgan | Anupam Rama60% | $19 → $21 | Maintains | Overweight | Get Alert |
| 11/13/2024 | Buy Now | 106.9% | Needham | Ami Fadia60% | $16 → $15 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | 134.48% | HC Wainwright & Co. | Robert Burns46% | $17 → $17 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | 120.69% | Needham | Ami Fadia60% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 09/24/2024 | Buy Now | 106.9% | Citigroup | David Lebowitz55% | $13 → $15 | Maintains | Buy | Get Alert |
| 09/05/2024 | Buy Now | 37.93% | Baird | Joel Beatty69% | $8 → $10 | Maintains | Neutral | Get Alert |
| 09/03/2024 | Buy Now | 134.48% | HC Wainwright & Co. | Robert Burns46% | $19 → $17 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | 162.07% | JP Morgan | Anupam Rama60% | $22 → $19 | Maintains | Overweight | Get Alert |
| 08/07/2024 | Buy Now | 148.28% | Needham | Ami Fadia60% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2024 | Buy Now | 148.28% | Needham | Ami Fadia60% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 162.07% | HC Wainwright & Co. | Robert Burns46% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 148.28% | Needham | Ami Fadia60% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 37.93% | Wedbush | David Nierengarten61% | $10 → $10 | Reiterates | Neutral → Neutral | Get Alert |
| 05/13/2024 | Buy Now | 162.07% | HC Wainwright & Co. | Robert Burns46% | $19 → $19 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 148.28% | Needham | Ami Fadia60% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2024 | Buy Now | 175.86% | JP Morgan | Anupam Rama60% | $18 → $20 | Maintains | Overweight | Get Alert |
| 02/26/2024 | Buy Now | 148.28% | Needham | Ami Fadia60% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | Buy Now | 79.31% | Citigroup | David Lebowitz55% | $11 → $13 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | 10.34% | Baird | Joel Beatty69% | $14 → $8 | Downgrade | Outperform → Neutral | Get Alert |
| 02/23/2024 | Buy Now | 37.93% | Wedbush | David Nierengarten61% | $5 → $10 | Maintains | Neutral | Get Alert |
| 02/12/2024 | Buy Now | 106.9% | Needham | Ami Fadia60% | $15 → $15 | Reiterates | Buy → Buy | Get Alert |
| 02/08/2024 | Buy Now | 51.72% | Citigroup | David Lebowitz55% | → $11 | Initiates | → Buy | Get Alert |
| 12/15/2023 | Buy Now | 79.31% | HC Wainwright & Co. | Robert Burns46% | $27 → $13 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | -31.03% | Wedbush | David Nierengarten61% | $20 → $5 | Downgrade | Outperform → Neutral | Get Alert |
| 12/08/2023 | Buy Now | 148.28% | JP Morgan | Anupam Rama60% | → $18 | Initiates | → Overweight | Get Alert |
| 12/05/2023 | Buy Now | 203.45% | Needham | Ami Fadia60% | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2023 | Buy Now | 203.45% | Needham | Ami Fadia60% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2023 | Buy Now | 203.45% | Needham | Ami Fadia60% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | Buy Now | 203.45% | Needham | Ami Fadia60% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/30/2023 | Buy Now | 272.41% | HC Wainwright & Co. | Robert Burns46% | → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 203.45% | Needham | Ami Fadia60% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/13/2023 | Buy Now | 258.62% | Guggenheim | Charles Zhu64% | → $26 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 203.45% | Piper Sandler | Christopher Raymond55% | → $22 | Maintains | Overweight | Get Alert |
| 06/08/2023 | Buy Now | 272.41% | HC Wainwright & Co. | Robert Burns46% | $28 → $27 | Maintains | Buy | Get Alert |
| 06/05/2023 | Buy Now | 189.66% | Needham | Ami Fadia60% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 189.66% | Needham | Ami Fadia60% | → $21 | Reiterates | Buy → Buy | Get Alert |
| 04/28/2023 | Buy Now | 175.86% | Baird | Joel Beatty69% | → $20 | Initiates | → Outperform | Get Alert |
| 04/19/2023 | Buy Now | 217.24% | Needham | Ami Fadia60% | → $23 | Maintains | Buy | Get Alert |
| 03/27/2023 | Buy Now | 286.21% | HC Wainwright & Co. | Robert Burns46% | → $28 | Assumes | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 258.62% | Guggenheim | Charles Zhu64% | → $26 | Reiterates | → Buy | Get Alert |
| 03/15/2023 | Buy Now | 217.24% | Needham | Ami Fadia60% | $24 → $23 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 175.86% | SVB Leerink | Andrew Berens48% | $18 → $20 | Maintains | Outperform | Get Alert |
| 12/14/2022 | Buy Now | 231.03% | Needham | Ami Fadia60% | → $24 | Initiates | → Buy | Get Alert |
| 12/13/2022 | Buy Now | 231.03% | Guggenheim | Charles Zhu64% | $22 → $24 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | 148.28% | SVB Leerink | Andrew Berens48% | $20 → $18 | Maintains | Outperform | Get Alert |
| 06/28/2022 | Buy Now | 106.9% | Guggenheim | Charles Zhou39% | → $15 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Cogent Biosciences (COGT) stock?
The latest price target for Cogent Biosciences (NASDAQ:COGT) was reported by Needham on June 17, 2025. The analyst firm set a price target for $0.00 expecting COGT to fall to within 12 months (a possible -100.00% downside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cogent Biosciences (COGT)?
The latest analyst rating for Cogent Biosciences (NASDAQ:COGT) was provided by Needham, and Cogent Biosciences reiterated their hold rating.
When was the last upgrade for Cogent Biosciences (COGT)?
There is no last upgrade for Cogent Biosciences
When was the last downgrade for Cogent Biosciences (COGT)?
The last downgrade for Cogent Biosciences Inc happened on December 11, 2024 when Needham changed their price target from $15 to $15 for Cogent Biosciences Inc.
When is the next analyst rating going to be posted or updated for Cogent Biosciences (COGT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cogent Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cogent Biosciences was filed on June 17, 2025 so you should expect the next rating to be made available sometime around June 17, 2026.
Is the Analyst Rating Cogent Biosciences (COGT) correct?
While ratings are subjective and will change, the latest Cogent Biosciences (COGT) rating was a reiterated with a price target of $0.00 to $0.00. The current price Cogent Biosciences (COGT) is trading at is $7.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
